Our advisors have supported early phase drug and new medical device concerns, as well as established healthcare companies with stable and growing earnings streams.  We have deep investor and analyst relationships across the space, and enjoy the industry’s complexity as it requires a strategic partner like Alpha IR to create a truly “best practices” approach.